Biologics Market Size, Future Opportunities, Emerging Trends, Growth And Forecast Report 2033

The biologics market size has grown strongly in recent years. It will grow from $416.65 billion in 2023 to $454.4 billion in 2024 at a compound annual growth rate (CAGR) of 9.1%. The growth in the historic period can be attributed to aging population, government initiatives, ability to command high prices, and increased need for immunology.

The biologics market size is expected to see rapid growth in the next few years. It will grow to $666.31 billion in 2028 at a compound annual growth rate (CAGR) of 10.0%. The growth in the forecast period can be attributed to increase in funding, technological advancements, increase in healthcare access, robust research and development activities for development of oral biologics, lean towards pills over injections, and increasing robust pipeline of biologics. Major trends in the forecast period include leveraging revised and less stringent regulations to develop new and improved biologics, shifting to biologic drug development to capitalize on the growing demand for these drugs, investing in r&d for the development of innovative biologics, and investing in research and development of biologics for the treatment of complex diseases.

Market Overview -
Biologics are medications made from organic materials that can be used to treat a wide range of illnesses, and they are frequently used to treat immune-related illnesses such Crohn's disease, psoriasis, ankylosing spondylitis, and rheumatoid arthritis. The interesting aspect is that biologics are separated from various natural sources, whether they be carbohydrates, proteins, nucleic acids, or a complex mixture of these materials.

Download Free Sample of Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=3606&type=smp

Personalized Medicine Fueling Growth In The Biologics Market
The demand for personalized medicine is driving significant growth in the global biologics market. Personalized medicine, also known as precision medicine, is a medical approach that tailors healthcare and medical treatment to the individual characteristics of each patient. The personalized medicine offers the ability to customize biologic treatments to a patient's specific genetic and clinical profile is transforming the healthcare landscape. For instance, according to the Personalized Medicine Coalition's report, in 2021 the personalized medicines accounted for over a third of new drug approvals in 2021, representing approximately 35% of all newly approved therapeutic molecular entities. Therefore, the increasing demand for personalized medicine is driving the growth of the biologics market going forward.

Competitive Landscape -
Major companies operating in the biologics market report are Merck & Co., Inc., AbbVie Inc., F. Hoffmann-La Roche AG, Johnson & Johnson, Pfizer Inc., Bristol Myers Squibb Company, Sanofi S.A., GlaxoSmithKline Plc., Eli Lilly and Company, Amgen Inc., Wockhardt, Zydus Cadilla, Asahi Glass Co. Ltd., China Biologic Products Holdings Inc., China Regenerative Medicine International, ABLbio, Adimmune, Henlius, Innovent Biologics, Bio-Thera, Hisun Pharma, 3SBio, Beijing ShuangLu Pharmaceuticals, Qilu Pharmaceutical, Shanghai Fosun Pharmaceuticals, Biocon, Dr.Reddy's, Mylan, Kyowa Hakko Kirin, Takeda, Mitsubishi Tanabe, AGC Biologics, Tonghua Dongbao Pharmaceutical Co., China Regenerative Medicine International, Shanghai Fosun Pharmaceuticals, Bayer AG, Novartis AG, BiosanaPharma, WuXi, Teva UK Limited, AstraZeneca, Abbott Laboratories, Vectura Group, Fujifilm, Lonza, Seqens, Piramal Pharma Solutions, Corden Pharma, Procos SpA and BSP Pharmaceuticals., Microgen, Geropharm, Valenta, NovaMedica, SynBi, Rani Therapeutics, Emisphere Technologies Inc., Enteris BioPharma, Allena Pharmaceuticals, Biogen Inc., Emisphere Technologies Inc., Biogen Inc., Novartis, Apotex, Gilead Sciences, Bayer, Abbott Laboratories

Biologics Market Driven By Innovative Product
Major companies operating in the biologics industry are focused on developing innovative products, such as, oncology biosimilar to strengthen their position and gain a competitive advantage. Oncology biosimilars are a type of biologic drug that is used to treat cancer. Biosimilars are highly similar copies of existing biologic drugs. For instance, in May 2022, Biocon Biologics Limited, a subsidiary of Biocon Limited, an India-based biopharmaceutical company and Viatris Inc., a US-based pharmaceutical company , launched Abevmy®, an oncology biosimilar, in Canada. Abevmy is a biosimilar medicine used for the treatment of cancer. Biosimilar medicines are biological medicines that are highly similar to another biological medicine that has already been authorized for use. They are used to treat the same conditions as the reference medicine and have the same safety and efficacy.

Browse Full Report @
https://www.thebusinessresearchcompany.com/report/biologics-global-market-report

Key Segments -
The biologics market covered in this report is segmented -
1) By Type: Monoclonal Antibodies (MAbS), Therapeutic Proteins, Vaccines
2) By Drug Classification: Branded Drugs, Generic Drugs
3) By Route Of Administration: Oral, Other Route Of Administration
4) By Mode Of Purchase: Prescription-Based Drugs, Over-The-Counter Drugs
5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Other Distribution Channels

Subsegments Covered: Anti-Cancer MAbS, Immunological MAbS, Anti-Infective Monoclonal Antibodies (MAbs), Neuropharmacological MABS, Cardiovascular And Cerebrovascular MAbS, Other Monoclonal Antibodies (MAbs), Metabolic Disorders Therapeutic Proteins, Cancer Therapeutic Proteins, Cardiovascular Therapeutic Proteins, Immunological Therapeutic Proteins, Other Therapeutic Proteins, Anti-Infective Vaccines, Autoimmunity Vaccines, Other Vaccines

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Want To Know More About The Business Research Company?

The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database

The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.